About Fatty acid hydroxylase domain-containing protein 2
Fatty acid hydroxylase domain-containing protein 2 (FAXDC2) is a protein
from Homo sapiens identified by UniProt accession
Q96IV6, 333 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Fatty acid hydroxylase domain-containing protein 2 |
|---|
| UniProt accession | Q96IV6 |
|---|
| Gene | FAXDC2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 333 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.23
- reticulocyte measurement · score 0.22
- adolescent idiopathic scoliosis · score 0.21
- mean corpuscular hemoglobin · score 0.20
- mean corpuscular hemoglobin concentration · score 0.12
- erythrocyte count · score 0.12
- age at menopause · score 0.10
- neoplasm · score 0.08
- reticulocyte count · score 0.06
- bowel opening frequency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96IV6-F1 | alphafold | PREDICTED | 92.21 | — |
Amino-acid sequence (333 residues)
MKGEAGHMLH NEKSKQEGHI WGSMRRTAFI LGSGLLSFVA FWNSVTWHLQ RFWGASGYFW QAQWERLLTT FEGKEWILFF IGAIQVPCLF FWSFNGLLLV VDTTGKPNFI SRYRIQVGKN EPVDPVKLRQ SIRTVLFNQC MISFPMVVFL YPFLKWWRDP CRRELPTFHW FLLELAIFTL IEEVLFYYSH RLLHHPTFYK KIHKKHHEWT APIGVISLYA HPIEHAVSNM LPVIVGPLVM GSHLSSITMW FSLALIITTI SHCGYHLPFL PSPEFHDYHH LKFNQCYGVL GVLDHLHGTD TMFKQTKAYE RHVLLLGFTP LSESIPDSPK RME
Explore Fatty acid hydroxylase domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets